Prognosis in patients with MDS or AML and bone marrow blasts between 10% and 30% is not associated with blast counts but depends on cytogenetic and molecular genetic characteristics In 2001, the World Health Organization (WHO) classification lowered the threshold for the definition of acute myeloid leukemia (AML) from 30% to 20% of bone marrow (BM) blasts, thus abandoning the category of refractory anemia with excess blasts in transformation (RAEB-T). This modification had been based on similarities in clinical outcomes of RAEB-T and AML patients. 1, 2 However, this repeatedly arbitrary threshold of 20% of BM blasts for separation of AML from myelodysplastic syndromes (MDSs) remained in continuous debate. 3 To further investigate its justification and potential relevance for diagnosis, prognosis and guidance of treatment decisions, we analyzed clinical outcomes and cytogenetic and molecular genetic features in 276 unselected and consecutive patients with 10-30% of BM blasts, as assessed by BM cytomorphology. The patients were investigated at the MLL Munich Leukemia Laboratory in the period of August 2005 to June 2010. The rationale for study inclusion was the availability of cytomorphology, chromosome-banding analysis/fluorescence in situ hybridization, and parallel PCR mutation analyses results for the markers FLT3-internal tandem duplication (ITD), NPM1 and MLL-PTD (partial tandem duplications). Additional molecular alterations in genes such as RUNX1, NRAS, FLT3-TKD (tyrosine kinase domain), CEBPA or IDH1, were investigated in certain subsets of patients, respectively. The total cohort included 170 males and 106 females (n ¼ 276; median age, 68.4 years; range 20.4-88.3 years). According to the 2008 WHO criteria, 96 patients were diagnosed as MDS RAEB-2, as they had 10-19% of myeloblasts, and 180 cases had a diagnosis of AML with 20-30% of myeloblasts (Table 1 ). Morphological subtypes of AML patients were as follows: M0: n ¼ 10; M1: n ¼ 2; M2: n ¼ 99; M4: n ¼ 23; and M6: n ¼ 15. Of note, French-American-British (FAB) criteria were not applicable in 31 cases in most cases because of the low cellularity. The WHO category entitled 'AML with recurrent genetic abnormalities' was excluded from the study, as the respective subentities are classified by the genetic alterations independent on blast percentages. Treatment of patients was performed according to standard therapy protocols and was adapted to clinical course (information available on 214 cases; MDS: n ¼ 73; AML: n ¼ 141). As anticipated, MDS patients had a higher rate of supportive care (27/73; 37.0% versus 22/141; 15.6%), and AML patients underwent more frequently intensive chemotherapy regimens (119/141; 84.4% versus 46/73; 63.0%). The number of allogeneic hematopoietic stem cell transplantations was 26 in AML and 11 in MDS. Patients gave written informed consent and the study was approved by the Bavarian Medical Association (Bayerische Landesärztekammer) and followed the Declaration of Helsinki.
All patients were analyzed by BM cytomorphology (May Giemsa Gruenwald staining) and cytochemistry (myeloperoxidase and nonspecific esterase). AML cases were classified according to FAB and WHO (2008) Immunophenotyping with multiparameter flow cytometry by five color staining was available in 197 cases. Microarray gene expression profiling data was generated on 26 cases using HG-U133 Plus 2.0 microarrays (Affymetrix, Santa Clara, CA, USA). Sample preparation and data analysis was performed as previously described (see online Supplement).
First, we compared the MDS (BM blasts 10-19%) and AML (BM blasts 20-30%) cohorts with respect to biological and clinical parameters. Median age did not differ significantly between the MDS and AML cohorts (68.8 versus 68.2 years). Similarly, no difference was observed with respect to peripheral blood parameters (white blood cell count: 2.9 versus 3.5 Â 10 9 /l; platelets: 71 versus 61 Â 10 9 /l, Hb 9.5 versus 9.6 g/dl). Second, we performed a comparison of cytogenetic results in the MDS and AML cohorts ( Figure 1 ). Aberrant karyotypes were similarly distributed in MDS and AML (MDS: 41/96; 42.7%; AML: 78/180; 43.3%; nonsignificant). Also, cytogenetic risk groups according to the revised Medical Research Council criteria 4 did not differ significantly between both categories: unfavorable karyotypes were detected in 22/96 (22.9%) of all MDS and in 41/180 (22.8%) of all AML cases. Similarly, there were no significant differences in the distribution of molecular mutations between both cohorts: This applied to the NPM1 mutation (MDS: 18/96; 18.8%; AML: 32/180; 17.8%), FLT3-ITD Table 1 Clinical characteristics, peripheral blood parameters, FAB subtypes of AML patients, karyotypes and molecular mutations of the 276 patients with MDS or AML and 10-30% of BM blasts investigated in this study Figure S1 ). Overall survival (OS) was first compared between the two above defined morphological subgroups according to a blast threshold of 20%. No significant difference was observed in the median OS between MDS and AML patients (34.4 versus 43.7 months; Figure 1A ). In contrast, when the total cohort was subdivided according to cytogenetics, as anticipated, patients with unfavorable karyotypes had significantly worse OS than those with intermediate karyotypes (median 13.9 versus 43.7 months; Po0.001; Figure 1B) . Importantly, the cytogenetic risk groups remained prognostically relevant when MDS (unfavorable versus intermediate karyotypes: median OS, 12.5 versus 34.9 months; Po0.001) and AML (unfavorable versus intermediate karyotypes: median OS, 19.0 versus 43.7 months; Po0.001) were separately investigated.
On focusing on the total cohort, the NPM1 mutated status conferred a better prognosis when compared with NPM1 wildtype patients (median OS not reached versus 27.3 months; P ¼ 0.005), whereas FLT3-ITD and MLL-PTD alterations had no significant influence on OS, because of the lower number of mutated patients for both markers. Furthermore, OS was better in the NPM1mut/FLT3-ITD-negative subgroup (n ¼ 41; median OS not reached) when compared with all other molecular subgroups (n ¼ 235; median 27.3 months; P ¼ 0.002; Figure 1C , Supplementary Table S1 ). The NPM1mut/FLT3-ITD negative patients had better median OS when compared with all other molecular subgroups also when AML (NPM1mut/FLT3-ITD negative: median OS not reached versus others: 1333 days; P ¼ 0.016) and MDS (NPM1mut/FLT3-ITD negative: median OS not reached versus others: 746 days; P ¼ 0.042) were separately investigated.
Comparison of immunophenotypes between AML and MDS cases revealed a higher expression of CD34 (26.7±20.5% versus 18.3 ± 15.8%; P ¼ 0.002) in AML cases, whereas there were no significant differences seen in the expression of other analyzed antigens, such as CD117, CD13 or CD13. Median Table S3B ). This analysis revealed a somewhat more distinctive heatmap, yet failed to achieve significance after adjustment for multiple testing. Overall, gene expression profiles of the AML versus MDS cases showed no statistically significant differences, while cases with intermediate versus unfavorable cytogenetics and cases with normal versus abnormal karyotypes (Supplementary Table S3C) showed a trend to separate into distinctive clusters.
In an univariate analysis investigating the total cohort, age (Po0.001), cytogenetic risk group (Po0.001), an NPM1-mutated status as sole parameter (P ¼ 0.008), NPM1mut/FLT3-ITD-negative status (P ¼ 0.005; considering the combination of both markers), and platelet count (P ¼ 0.018) were prognostically relevant regarding OS. In contrast, subdivision of cases according to cytomorphologic criteria separating patients either according to the MDS versus AML categories (10-19% versus 20-30% of BM blasts), white blood cell count, hemoglobin, CD34 þ counts, and the FLT3-ITD (as single parameter), MLL-PTD and RUNX1 mutation status had no relevance. In a multivariate analysis, only age (P ¼ 0.048), cytogenetic risk group (P ¼ 0.010) and platelets (P ¼ 0.033) were proven to confer independent prognostic relevance with regards to OS (Table S2) .
The decision of the WHO in 2001 to exclude the RAEB-T category and to separate MDS and AML by 20% of BM blasts had been based on the similar clinical outcomes of patients with RAEB versus RAEB-T or AML, 2 and the observation that response to chemotherapy was strongly dependent on parameters such as age or cytogenetics if compared with the cytomorphologic subcategories.
1 Therefore, the WHO guidance succeeded to focus their criteria more (strongly) on the clinical characteristics and the genetic background of the different myeloid malignancies and to facilitate the separation of MDS and AML cases. Yet, as suggested by Albitar et al. 3 despite these clinical similarities, the removal of the former RAEB-T category did Letters to the Editor not take the biologic and genetic differences of RAEB-T and AML into account, for example, with regards to higher CASP3 (caspase 3) activity, higher levels of cell proliferation, and higher rates of poor risk cytogenetics in the RAEB-T patients, if compared with AML with 430% BM blasts. Therefore, RAEB-T seemed to have a closer relationship to advanced MDS than to AML. According to Albitar et al., 3 these differences in the biologic and genetic features of both entities should not be neglected as therapy might undergo changes, but the biological features of the distinct hematological entities do not.
Although some hematologists still assign patients to the RAEB-T category when defining diagnostic criteria for application of therapeutic compounds, for example, azacytidine, 5 the assignment of patients with borderline blasts to either AML or MDS categories according to the recent WHO guideline has a strong influence on therapeutic decisions or at least the 'gut feeling' of hematologists with regard to this specific subgroup of patients. In contrast, the results from our study comparing clinical, biological and genetic aspects in a large cohort of patients with MDS and AML and borderline blasts between 10-30% respectively, were indicative of overlapping characteristics ignoring the arbitrary 20% blast threshold: This applied first to a similar distribution of cytogenetic risk groups, 4 and of the molecular mutation profiles including an extended marker panel (NPM1, FLT3-ITD/TKD, MLL-PTD, NRAS, CEBPA, RUNX1 and IDH1). The frequencies of the NPM1 mutation and FLT3-ITD were markedly lower in our AML cohort that had been selected according to low blast proportions, when compared with overall AML cohorts published, but had been comparable with our MDS subgroup. Furthermore, the subdivision of all patients according to the WHO threshold of 20% of BM blasts failed to determine prognostically different subgroups even if treatment was not fully comparable. In contrast, biological parameters such as age, the cytogenetic risk group and the NPM1mut/FLT3-ITD-negative status were prognostically relevant in univariate analysis. In multivariate analysis on the total cohort, only age (P ¼ 0.048), cytogenetic risk group 4 (P ¼ 0.010) and platelets (P ¼ 0.033) remained significant parameters for the prediction of prognosis. Of note, the percentage of blasts using the categories 10-19% versus 20-29% had no significant impact.
In conclusion, these data emphasize the biological, cytogenetic and molecular similarities of MDS and AML with borderline blast percentages between 10-30%. Currently, therapeutic concepts already assign patients to specific treatment regimens across the borders of the different disease categories: For example, azacytidine has been approved by the Food and Drug Administration for use in patients with different MDS subtypes, as well as RAEB-T and CMML with blasts up to 30%Fwhat would be categorized as AML if blasts exceed 20%. 6 Today, patients with intermediate-2 or high-risk IPSS (international prognostic scoring system) MDS are considered to be candidates for allogeneic hematopoietic stem cell transplantation as first-line therapy. 7 Therefore, instead of trying to define arbitrary blast thresholds for the separation of MDS from AML, the investigation of karyotypes and molecular alterations such as NPM1 mutations and FLT3-ITD might have an advantage for risk stratification and therapeutic decisions for these patients in the gray area of AML and MDS. These approaches might be catalyzed by the increasing panel of novel molecular markers in both entities and individualized treatment strategies, such as best supportive care, azacytidine, 8 standard AML treatment protocols and allogeneic stem cell transplantation.
